Covid-19: Indian developed vaccine more expensive

In India on 14/01/2021 at 11:17 am

Covishield, the AstraZeneca vaccine manufactured by the Serum Institute of costs the Indian govt Rs200 (US$2.7). Covaxin the the vaccine indigenously developed by Bharat Biotech costs Rs206 a dose: 3% more.

And don’t forget, India has not fully approved Covaxin– India’s Covid-19 vaccination: Do you feel lucky?

  1. Covaxin phase 3 preliminary efficacy is 60+%.

    Hopefully they’re not doing another Sinovac where asymptomatic & mild infections were discounted.

    The Sinovac phase 3 trial in Brazil has clarified that Sinovac’s actual empirical efficacy was only 50.4% —- an almost 28 percentage point reduction from the much-heralded initial broadcast of 78%.

    Singapore’s HSA will likely approve Moderna’s shot by next week.

    I predict there’ll be a mad rush of 3+ million sinkies for mass vaccination by end-Jan, when you know for sure you’ll be getting the 2 best-in-class vaccines so far. Nobody wants to wait for potentially inferior candidates like Sinovac to be potentially approved. And then you’ll have to play the Clint Eastwood truth or dare game.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: